0.28 (4.75%)Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Neutral
Value
Consensus
Price
Very Weak
Earnings
Very Weak
Earnings
Very Weak
Dividends
Very Weak
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Website
Xeris Biopharma Holdings, Inc.
Telephone
1.844.445.5704
Address
Suite 1300, 1375 West Fulton Street, Chicago, IL 60607
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 4.32 - 10.09
Trade Value (12mth)
US$6,523.00
1 week
-2.53%
1 month
4.47%
YTD
-15.25%
1 year
26.37%
All time high
10.09
EPS 3 yr Growth
-100.50%
EBITDA Margin
12.90%
Operating Cashflow
$29m
Free Cash Flow Return
11.80%
ROIC
0.20%
Interest Coverage
1.30
Quick Ratio
1.60
Shares Outstanding (Fully Diluted)
178m
HALO Sector
Healthcare
Next Company Report Date
N/A
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.00
Historical data
Forecast data
| 2021 | 2022 | 2023 | 2024 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||||
| Per Share, Growth & Valuations | |||||||||||||
EPS (Basic) | GBP |  | | | | -0.45 | -0.37 | N/A | | | | ||
EPS (Fully Diluted) | GBP | | | | | -0.45 | -0.37 | N/A | | | | ||
Growth | % | | | | | 35.2 | 17.4 | 100.9 | | | | ||
PE | X | | | | | N/A | N/A | 2,453.1 | | | | ||
EV/EBITDA | X | | | | | N/A | N/A | 39 | | | | ||
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
